JPRN-jRCT2031210645已完成3 期
A Phase 3, Randomized, Multicenter, Open-label, Active-comparator Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - PEGASUS
Machaidze Zurab0 个研究点目标入组 10 人开始时间: 2022年3月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
This was a prospective, randomized, multicenter, open-label, active-comparator controlled study. The primary objectives of this study were to establish the efficacy and safety of pegcetacoplan compared to eculizumab in patients with PNH who continued to have Hb levels <10.5 g/dL despite treatment with eculizumab. The results of the study successfully demonstrated that pegcetacoplan, at a dosage of 1080 mg subcutaneously twice weekly, was superior to eculizumab in improving Hb levels in these patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. At least 18 years of age
- •2. Primary diagnosis of PNH confirmed by high-sensitivity flow cytometry
- •3. On treatment with eculizumab. Dose of eculizumab must have been stable for at least 3 months prior to the screening visit
- •4. Hb <10.5 g/dL at the screening visit
- •5. Absolute reticulocyte count >1.0 x ULN at the screening visit
- •6. Platelet count of >50,000/mm3 at the screening visit
- •7. Absolute neutrophil count >500/mm3 at the screening visit
- •8. Vaccination against Neisseria meningitidis types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with pegcetacoplan. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits
- •9. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening and Day -28 visit (run-in period) and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after their last dose of study drug
- •10. Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug
- •11. Willing and able to give informed consent
- •12. Willing and able to self-administer pegcetacoplan (administration by caregiver will be allowed)
- •13. Have a body mass index (BMI) <35.0 kg/m2
排除标准
- •1. Active bacterial infection that has not resolved within 1 week of Day -28 (first dose of pegcetacoplan)
- •2. Receiving iron, folic acid, vitamin B12 and EPO, unless the dose is stable, in the 4 weeks prior to screening
- •3. Hereditary complement deficiency
- •4. History of bone marrow transplantation
- •5. History or presence of hypersensitivity or idiosyncratic reaction to compounds related to the investigational product or SC administration
- •6. Participation in any other investigational drug trial or exposure to other investigational agent within 30 days or 5 half-lives (whichever is longer)
- •7. Currently breast-feeding women
- •8. Inability to cooperate or any condition that, in the opinion of the investigator, could increase the subjects risk of participating in the study or confound the outcome of the study
- •This study includes cardiac safety evaluations. The following cardiac eligibility criteria are necessary to avoid confounding the cardiac safety outcomes:
- •9. History or family history of Long QT Syndrome or torsade de pointes, unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden death
- •10. Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Class 2 Angina Pectoris or NYHA Heart Failure Class >2
- •11. QTcF >470 ms, PR >280 ms
- •12. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities
- •13. Receiving Class 1 or Class 3 antiarrhythmic agents, or arsenic, methadone, ondansetron or pentamidine at screening
- •14. Receiving any other QTc-prolonging drugs (see Appendix 4), at a stable dose for less than 3 weeks prior to dosing
- •15. Receiving prophylactic ciprofloxacin, erythromycin or azithromycin for less than one week prior to the first dose of study medication (must have a repeat screening ECG after one week of prophylactic antibiotics with QTcF <470 ms)
研究者
相似试验
进行中（未招募）
3 期
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceEssential ThrombocythemiaNCT04285086PharmaEssentia174
已完成
3 期
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaMultiple MyelomaNCT03110562Karyopharm Therapeutics Inc402
进行中（未招募）
3 期
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLPeripheral T Cell LymphomaNCT04668690CSPC ZhongQi Pharmaceutical Technology Co., Ltd.193
招募中
3 期
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCNon-small Cell Lung CancerNCT06671379Suzhou Suncadia Biopharmaceuticals Co., Ltd.500
已完成
3 期
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®Prostate CancerNCT04563936Luye Pharma Group Ltd.290